Global Factor VIII Supply To Improve Following European Commission Approval, Release of Additional Supply
European Commission Approves Wyeth's U.S. Recombinant Factor VIII Production Facility and European Recombinant Factor VIII Final Processing Facility

Madison, N.J., USA (May 6, 2002) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that its recombinant factor VIII production facilities in St. Louis, Missouri, USA, and Algete, Spain, have both received approval from the European Commission. These facilities will increase the global supply of ReFacto^® (moroctocog alfa, recombinant coagulation factor VIII) - the Company's recombinant factor VIII product for the treatment of hemophilia A.

Following a $200 million USD investment to expand its production capacity and enhance its manufacturing technology, Wyeth estimates that additional supplies of ReFacto will be available immediately, thereby helping to ease the global shortage of recombinant factor VIII product.

"We have made a substantial investment in our biopharmaceutical production facilities so we can ensure a reliable, high-quality supply of our hemophilia products," says L. Patrick Gage, PhD, President, Wyeth Research. "These approvals are the next step in helping to resolve the global shortage of recombinant factor VIII products for hemophilia A patients and we are pleased to be part of that solution."

The ReFacto Manufacturing Process
The manufacture of ReFacto is a complex process involving a number of biological stages utilizing the most advanced technology. Until now, all ReFacto sold in the United States and Europe was produced in Stockholm, Sweden. With the final EC regulatory approval, additional quantities of ReFacto will be produced at the biopharmaceutical facilities in St. Louis and Algete. As the St. Louis and Algete facilities are able to increase the amount of ReFacto available to the European Union, more product from the Stockholm facility will be available to the U.S. and the rest of the world. We are working diligently to achieve approval to distribute ReFacto from our St. Louis facility in the U.S. as well.

About ReFacto
ReFacto is a recombinant factor VIII product formulated without the addition of human serum albumin in its final formulation. In the European Union, ReFacto is indicated for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A. The product received marketing authorization from the EC in 1999. In the United States, ReFacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis in hemophilia A patients and for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes. The effect of regular routine prophylaxis in long-term morbidity and mortality is unknown. The U.S. Food and Drug Administration approved ReFacto for marketing in 2000. During clinical trials, ReFacto had a safety profile comparable to other factor VIII products. As with the intravenous administration of any protein product, adverse reactions may include headache, fever, chills, flushing, nausea, vomiting, lethargy, or manifestations of allergic reactions.

Hemophilia is a genetically inherited blood clotting disorder caused by a deficiency in specialized proteins instrumental in promoting the normal clotting process. Hemophilia A, the most common form of the disorder, is the result of a deficiency in the clotting factor protein referred to as factor VIII. Hemophilia A affects around 1 in 5,000 males around the world.

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, hemophilia, oncology and vaccines.

Wyeth (NYSE:WYE) is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Back to News Archives